Drug Treatment of Metaboilic Syndrome Term Paper

Patient and family education is essential especially with regards to eating habits. The patients should avoid excess fat in their diet as it contributes to high chances of contracting the disease (Bolen et al. 2010). The drug has, however, remained on the market in the U.S. The drug has been removed from European markets due to escalating concerns regarding safety. Obesity has considerable contribution to the number of preventable deaths in the United States. In essence, obesity is a condition whereby the affected being has a body mass index (BMI) that exceeds 30. Apparently, BMI refers to the measure of a person's body relative to his or her height (Bolen et al. 2010).

The United States and several other economies of the world spend hefty sums of money in their budget estimates towards treatment and general containment of obesity, hypertension, diabetes II and other causes of preventable deaths. Americans have spent billions of dollars towards research and development (Carter et al. 2012). The outcome of it has been the discovery of various drugs that could be used towards prevention and obesity treatment. According to researchers and health care pundits, the American society and other societies of the world feature abundant food materials.

Physical activity is typically an option to the majority of the people (Carter et al. 2012). Illnesses resulting from obesity have compromised the performance of employees of various business organizations leading to alarming increases in the number of absentee employees with the disease and related ailments. Nearly one third of Americans are obese. Hence, urgent medical attention would be necessary towards reclaiming the growth in the number of victims of obese. Every year, millions of Americans spend billions of dollars on dieting, diet pills, diet foods, diet books, and other forms of preventive measures to avert the risk of contracting the disease (Carter et al. 2012).

References

Aronson, J.K. (2011). Side effects of drugs annual: A worldwide yearly survey of new data in adverse drug reactions. Amsterdam: Elsevier.

Bolen, S., Clark, J., Richards, T., Shore, a., Goodwin, S., & Weiner, J. (2010). Trends in and patterns of obesity reduction medication use in an insured cohort. Obesity (Silver Spring,

Md.), 18(1), 206-209.

Carter, R., Mouralidarane, a., Ray, S., Soeda, J., & Oben, J. (2012). Recent advancements in drug treatment of obesity. Clinical Medicine, 12(5), 456-460.

Codario, R.A. (2011). Type 2 diabetes, pre-diabetes, and the metabolic syndrome. New York:

Humana Press.

Davidson, J.K. (2010). Clinical diabetes mellitus: A problem-oriented approach. New York

[u.a.: Thieme.

Huizinga, M., Bleich, S., Beach, M., Clark, J., & Cooper, L. (2010). Disparity in physician

perception of patients' adherence to medications by obesity status. Obesity (Silver Spring,

Md.), 18(10), 1932-1937.

Izzo, J.L. (2007). Hypertension primer. Philadelphia, Pa: Lippincott Williams & Wilkins.

Lilly, L.S., & Harvard Medical School. (2011). Pathophysiology of heart disease: A

collaborative project of medical students and faculty. Baltimore, MD: Wolters

Kluwer/Lippincott Williams & Wilkins.

Mutnick, a.H. (2004). Hypertension management for the primary care clinician. Bethesda, Md:

American Society of Health-System Pharmacists.

Porth, C., & Hannon, R.A. (2009). Porth pathophysiology: Concepts of altered health states.

Philadelphia, Pa: Lippincott Williams & Wilkins.

Sharma, a. (2008). A weighty issue: medication as a cornerstone of medical obesity management. Canadian Family Physician Medecin De Famille Canadien, 54(4), 498.

Stanley, S.H., & Laugharne, J.E. (2012).…